Oncotelic Therapeutics to Showcase Nanomedicine Platform at BIO-Europe Spring 2026

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization.

The presentation at this major biotechnology conference represents a significant opportunity for Oncotelic to attract investment and collaboration for its innovative platform. The Deciparticle technology aims to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. This approach could potentially transform how existing cancer drugs are administered, making treatments more effective while reducing side effects.

Sapu Nano's platform presentation comes at a critical juncture as both lead candidates progress through early clinical development. Sapu003, currently in Phase 1 trials, represents an important step in validating the platform's capabilities with an established oncology drug. The advancement of Sapu006 into Phase 1 trials demonstrates the platform's versatility and potential application across multiple therapeutic agents. These developments are particularly noteworthy given the growing importance of targeted drug delivery systems in oncology, where precision medicine approaches are increasingly valued.

The company's participation in BIO-Europe Spring 2026 provides a platform to showcase its technology to potential partners who can help accelerate development and bring these innovations to market. Strategic partnerships could provide the resources and expertise needed to advance the clinical programs more rapidly and expand the platform's applications. The conference typically attracts pharmaceutical companies, investors, and research organizations seeking innovative technologies, making it an ideal venue for Oncotelic to demonstrate the potential of its Deciparticle platform.

For investors and stakeholders, the latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The full press release containing additional details about the presentation can be accessed at https://ibn.fm/Slq47. These resources provide comprehensive information about the company's progress and strategic direction as it prepares for this important industry event.

The significance of this announcement extends beyond the immediate conference presentation. It represents a milestone in Oncotelic's efforts to establish its nanomedicine platform as a viable approach to improving cancer treatment. Successful demonstration at BIO-Europe could lead to valuable partnerships that accelerate development timelines and potentially bring these innovations to patients sooner. The company's focus on enhancing therapeutic index through improved drug delivery addresses a fundamental challenge in oncology treatment, where balancing efficacy with toxicity remains a persistent concern.